ReviewHandbook of clinical neurology2012
Translational spinal cord injury research: preclinical guidelines and challenges.
Review in Handbook of clinical neurology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Neuroinflammatory regulatory role of microglia in optic nerve injury: from pathological mechanisms to therapeutic targets.Frontiers in immunology · 2026Review
- Histopathological Insights into Demyelination and Remyelination After Spinal Cord Injury in Non-human Primates.Neuroscience bulletin · 2025Article
- Review
- Gene-Modified Stem Cells for Spinal Cord Injury: a Promising Better Alternative Therapy.Stem cell reviews and reports · 2022Review
- Correlation Analysis Between Magnetic Resonance Imaging-Based Anatomical Assessment and Behavioral Outcome in a Rat Contusion Model of Chronic Thoracic Spinal Cord Injury.Frontiers in neuroscience · 2022Article
- Spastin interacts with collapsin response mediator protein 3 to regulate neurite growth and branching.Neural regeneration research · 2021Article
- Corticospinal Motor Circuit Plasticity After Spinal Cord Injury: Harnessing Neuroplasticity to Improve Functional Outcomes.Molecular neurobiology · 2021Review
- Heparin-Binding Growth-Associated Molecule (Pleiotrophin) Affects Sensory Signaling and Selected Motor Functions in Mouse Model of Anatomically Incomplete Cervical Spinal Cord Injury.Frontiers in neurology · 2021Article
- Article
- Adaptive trial designs for spinal cord injury clinical trials directed to the central nervous system.Spinal cord · 2020Review
- Behavioral testing in animal models of spinal cord injury.Experimental neurology · 2020Review
- Spinal cord stimulation for the restoration of bladder function after spinal cord injury.Healthcare technology letters · 2020Article
- Innovative mouse model mimicking human-like features of spinal cord injury: efficacy of Docosahexaenoic acid on acute and chronic phases.Scientific reports · 2019Article
- The Effect of Non-Gabapentinoid Anticonvulsants on Sensorimotor Recovery After Human Spinal Cord Injury.CNS drugs · 2019Observational
- Functional Multipotency of Stem Cells and Recovery Neurobiology of Injured Spinal Cords.Cell transplantation · 2019Article
- Article
- A rodent brain-machine interface paradigm to study the impact of paraplegia on BMI performance.Journal of neuroscience methods · 2018Article
- Translational Challenges of Rat Models of Upper Extremity Dysfunction After Spinal Cord Injury.Topics in spinal cord injury rehabilitation · 2018Review
- Multivariate Analysis of MRI Biomarkers for Predicting Neurologic Impairment in Cervical Spinal Cord Injury.AJNR. American journal of neuroradiology · 2017Article
- Rat models of spinal cord injury: from pathology to potential therapies.Disease models & mechanisms · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Advances in the neurobiology of spinal cord injury (SCI) have prompted increasing attention to opportunities for moving experimental strategies towards clinical applications. Preclinical studies are the centerpiece of the translational process. A major challenge is to establish strategies for achieving optimal translational progression while minimizing potential repetition of previous disappointments associated with clinical trials. This chapter reviews and expands upon views pertaining to preclinical design reported in recently published opinion surveys. Subsequent discussion addresses other preclinical considerations more specifically related to current and potentially imminent cellular and pharmacological approaches to acute/subacute and chronic SCI. Lastly, a retrospective and prospective analysis examines how guidelines currently under discussion relate to select examples of past, current, and future clinical translations. Although achieving definition of the "perfect" preclinical scenario is difficult to envision, this review identifies therapeutic robustness and independent replication of promising experimental findings as absolutely critical prerequisites for clinical translation. Unfortunately, neither has been fully embraced thus far. Accordingly, this review challenges the notion "everything works in animals and nothing in humans", since more rigor must first be incorporated into the bench-to-bedside translational process by all concerned, whether in academia, clinical medicine, or corporate circles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.